Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05310045
Other study ID # PREV-AIDANT
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date April 4, 2022
Est. completion date December 2023

Study information

Verified date December 2022
Source Centre Leon Berard
Contact Béatrice FERVERS
Phone +33 4.78.78.28.00
Email beatrice.fervers@lyon.unicancer.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Today, 40% of cancers are linked to modifiable risk factors and could thus be preventable. Primary prevention, which allows individuals to be informed and aware of health recommendations and possible actions before the onset of a cancer, is thus a major public health issue. Around 11 million of French citizens are informal caregivers, i.e. people who regularly and frequently provide a non-professional help to do all or part of daily life activities for a dependent person with a disability, disease, or due to age. In cancer, there are around 5 million of informal caregivers in France. Studies have shown that informal caregivers of cancer patients are not only at risk for stress, anxiety, poor health, diminished quality of life, but also that they adopt so-called "risk behaviours" (e.g., increased smoking or alcohol consumption, unbalanced eating habits rich in fat, sugar and ultra-processed foods, sedentary lifestyle, etc.). These behaviours may develop or worsen co-morbidities and/or promote cancer development, outside hereditary context. Moreover, for certain types of cancer, related and unrelated family caregivers have a higher risk of developing cancer because they share the same lifestyle including the same risk factors. However, compared to general population, informal caregivers of cancer patients, have an increased risk perception and motivation to change a so-called unhealthy lifestyle. In this context, our goal is to test the feasibility and acceptability of a personalised primary prevention intervention designed to informal caregivers of cancer patients at increased risk of cancer. The intervention will be first designed to first-degree relatives and partners/spouses of a patient treated at Léon Bérard Center. Developed in the Léon Bérard comprehensive cancer centre in close relation with outpatient care and based on an informal caregiver's tracking questionnaire, the intervention will be composed of two consultations with a physician trained in primary prevention and information and referral to health prevention structures. As primary objectives, acceptability will be assessed based on informal caregivers' satisfaction and feasibility based on their participation rates. As secondary objectives, informal caregivers' knowledge and risk perception will be assessed based on questionnaires and intention to change or change behaviour will be noted and analysed through individual semi-structured interviews.


Recruitment information / eligibility

Status Recruiting
Enrollment 130
Est. completion date December 2023
Est. primary completion date December 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - First-degree relative and partner/spouse of a patient treated at the Centre Léon Bérard; - At increased risk of cancer - Aged between 18 and 75 years; - No diagnosis of genetic predisposition to cancer and no personal or informal history suggesting genetic predisposition; - Able to complete a questionnaire in French, alone or with the help of a relative (persons with visual, mute, motor, hearing or intellectual disabilities will be included as long as they are able to complete a questionnaire alone or with the help of a relative); - Being informed and not opposed to the study ; - Having completed the entire tracking questionnaire and wishing to be contacted. Exclusion Criteria: - Related or unrelated relative not considered as an informal caregiver for the patient; - Minor informal caregiver; - Informal caregiver with a history of cancer; - Patient under care at the Institute of Hematology and Pediatric Oncology; - Individuals of legal age protected by law.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Personalised primary prevention intervention
Personalised primary prevention intervention Consultation 1 Assess caregiver's situation regarding their cancer risk factors Explain the causal links between risk factors and cancer Inform about national recommendations to prevent and limit cancer risk Clarify informal caregiver situation with respect to national screening programs Define a personalised primary prevention program Implementation: personalised primary prevention program Carried out by the informal caregiver Supervised by the coordinating nurse Consultation 2 Assess prevention actions realised by informal caregiver in relation to actions defined in the personalised primary prevention program Identify barriers and facilitators to their implementation whether actions or no actions have been done. Adapt the personalised primary prevention program to informal caregiver needs.

Locations

Country Name City State
France Centre Leon Berard Lyon

Sponsors (1)

Lead Sponsor Collaborator
Centre Leon Berard

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Acceptability of the intervention Acceptability will be assessed based on informal caregivers' satisfaction. At the end of the personalised primary prevention intervention (4 to 6 months after inclusion)
Primary Feasibility of the intervention Feasibility will be assessed based on informal caregivers' participation rates. At the end of the personalised primary prevention intervention (4 to 6 months after inclusion)
Secondary Adherence of informal caregivers to the different stages of the study: filling in the questionnaire Informal caregivers are identified with a tracking questionnaire. The percentage of informal caregivers who responded to the tracking questionnaire will be measured. At the pre-inclusion
Secondary Adherence of informal caregivers to the different stages of the study: attendance to consultations The personalised primary prevention intervention is composed of 2 consultations. The percentage of informal caregivers who participated to the 1st and 2nd consultation will be measured. At the end of the 1st (2 to 6 weeks after inclusion) and the 2nd consultation (4 to 6 months after inclusion)
Secondary Experience, of informal caregivers who have benefited from all the personalised primary prevention intervention Experience will be analysed using individual semi-structured interviews. After the 2nd consultation (4 to 6 months after inclusion)
Secondary Short-term impact of the personalised primary prevention intervention: knowledge Knowledge will be measured by informal caregiver's through a knowledge score based on a questionnaire. Before the 1st (2 to 6 weeks after inclusion) and the 2nd consultation (4 to 6 months after inclusion)
Secondary Short-term impact of the personalised primary prevention intervention: cancer risk perception Cancer risk perception will be measured by informal caregiver's through a cancer risk perception score, based on a questionnaire. Before the 1st (2 to 6 weeks after inclusion) and the 2nd consultation (4 to 6 months after inclusion)
Secondary Short-term impact of the personalised primary prevention intervention: Intention/behaviour change Intention/behaviour change will be measured by the percentage of actions planned in the personalised primary prevention programme and actually carried out by the informal caregiver. During the second consultation (4 to 6 months after inclusion)
See also
  Status Clinical Trial Phase
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1